Outcomes of High-Grade Glioma Patients in a Phase 1 Trial of BXQ-350, Cancer-selective SapC-DOPS Nanovesicles > View
First-in-human, First-in-Class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas > View
First-in-human, First-in-class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas. > View
Absence of Indicators of Hypercoagulability and Anti-phospholipid Syndrome in BXQ-350 First in Human Study. > View
Allometric Scaling of Preclinical Pharmacokinetic and Toxicokinetic Parameters to Predict Clinical Pharmacokinetics of BXQ-350 Saposin C Protein-Phosphatidylserine Nanovesicles. > View
Combined Effect of Gemcitabine (GEM) and SapC-DOPS Nanovesicles on Pancreatic Ductal Adenocarcinoma (PDAC) in Mice. > View
Safety and Pharmacokinetics of BXQ-350 in a Phase 1a and 1b Trial of Solid Tumors and High-grade Glioma. > View
High-Grade Glioma outcomes in the Phase 1 BXQ-350 trial of cancer-selective SapC-DOPS nanovesicles > View
